Avanir Pharma Announces Enrollment Of First Patient In AVR-133 Study

(RTTNews) - Avanir Pharmaceuticals, Inc. (AVNR) Tuesday announced the enrollment of the first patient in study AVR-133, a proof of concept, Phase II clinical trial investigating the use of AVP-923 for the treatment of levodopa induced dyskinesia or LID in patients with Parkinson's disease or PD.

AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide plus low-dose quinidine sulfate, which serves to increase the bioavailability of dextromethorphan.

AVP-923 is being studied in several ongoing company sponsored Phase II clinical trials including agitation in Alzheimer's disease and neuropathic pain in Multiple Sclerosis.

Top line data for this study is expected in the second half of calendar 2014.